China Times (www.chinatimes. Net.. CN.) Reporter Yu Na reports from Beijing
On March 21, the opening of “Bulao medicine” NMN concept stocks ushered in a sharp rise. As of the closing of the day, the stock price of Hunan Er-Kang Pharmaceutical Co.Ltd(300267) rose by 20%, the limit of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Shaanxi Kanghui Pharmaceutical Co.Ltd(603139) rose, Xiamen Kingdomway Group Company(002626) , Xiwang Foodstuffs Co.Ltd(000639) hit the limit, and Brother Enterprises Holding Co.Ltd(002562) , Shanghai Xuerong Biotechnology Co.Ltd(300511) and other stocks rose one after another.
In terms of news, the nmpa of the State Food and Drug Administration recently publicized the information that NMN substances can be used as new raw materials for “cosmetics”, which released a positive signal for the industry.
Citic Securities Company Limited(600030) pointed out that with the continuous promotion of anti-aging products in the future, the long-term market of the industry is expected to reach 100 billion, and the domestic enterprises taking the lead in layout are expected to have comprehensive competitive advantages in the future.
Cao Zhengzheng, a senior health manager, said that at present, the hot spot in China’s NMN product market demand is related nutritional and health food. Once policy support is obtained in the future, the industry will usher in explosive growth
nmn concept is favored by the market again
At present, dozens of A-share listed companies are involved in NMN business. On Friday, Xiamen Kingdomway Group Company(002626) , Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) and other NMN concept stocks strengthened during the session. This week, the NMN concept won the favor of the market again. The three indexes collectively opened higher, while the NMN concept led the rise. Several stocks in the sector “Xi ti” connected to the board, Hunan Er-Kang Pharmaceutical Co.Ltd(300267) , Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Shaanxi Kanghui Pharmaceutical Co.Ltd(603139) strong limit.
The full name of NMN is β- At present, NAD + is recognized as a highly effective substance in various foods and can be transformed into natural nicotinamide. The latest research shows that the NAD + concentration in the human body will decrease with the increase of age, and the decrease of NAD + concentration may lead to the decline of various human functions, such as nerve decline, vision decline, obesity, heart function decline and so on.
NMN can support NAD + production, activate sirtuins, repair NDA damage, promote vascular regeneration, maintain vascular elasticity, enhance endurance and vitality, help weight management, promote heart health, improve vision and immune function, so as to achieve the effects of slowing down aging and health gain.
Harvard University laboratory found that taking the substance to 22 month old mice can reverse the function of mitochondria in their muscles back to the level of 6 months old, which is equivalent to restoring the level of human from 60-70 years old to 20-30 years old. It is this study that gives them the title of “elixir of youth”.
In recent years, the research on NMN outside China has only increased. The concept of NMN was once sought after by the market, but it was stopped because of the regulation of relevant fields.
Now there is a turnaround. The nmpa of the State Food and Drug Administration recently publicized the information that NMN substances can be used as new raw materials for cosmetics. The filing company shows that Yuyao lefosbon Health Technology Co., Ltd. is a wholly-owned subsidiary under the name of “immortal pharmaceutical” gene port. Industry insiders said that the adoption of the filing may mean that the supervision of relevant fields is being relaxed.
Statistics show that the upstream of NMN industrial chain is dominated by raw material providers such as nicotinamide, ATP and bottled consumables. The middle of the industrial chain mainly refers to production enterprises, which are divided into two modes: OEM and independent production. The downstream main bodies are sales channels and consumers.
As early as 2015, the core concept stock Xiamen Kingdomway Group Company(002626) in NMN has acquired DBH and other overseas health care products enterprises, thus obtaining an out of policy channel to get involved in the field of NMN. The NMN of doctors best, a subsidiary, has been sold on Amazon, jd.com and tmall Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) the NMN products developed by Xianqiang pharmaceutical, a wholly-owned subsidiary, have also been listed for sale.
niacin, a wholly-owned subsidiary of Hunan Er-Kang Pharmaceutical Co.Ltd(300267) has passed the GMP on-site inspection and can be used in NMN production. Nicotinic acid, also known as vitamin B3, can be used as a pharmaceutical intermediate in the production of NMN Brother Enterprises Holding Co.Ltd(002562) disclosed on the interactive platform that the company has built an annual production project of 8000 tons of nicotinamide.
Minsheng Securities believes that, on the one hand, the approval of NMN means the official recognition of its strong efficacy. On the other hand, the concept of efficacy components of downstream brands is homogenized. Relevant brands are making early layout to strive for first mover advantages in NMN, and the NMN industry may usher in a new blue Ocean.
can the market extend to health products
It is worth noting that the NMN used for the record is related to cosmetics, but there is no information that can be used for health products, food, etc. However, industry insiders said that the rise of NMN concept stocks also shows that the market focus still lies in whether there is an opportunity to extend from cosmetics to health products in the future.
According to AI media consulting data, NMN has a certain market in China. In 2020, the market scale of China’s NMN component health products reached 5.106 billion yuan, with a year-on-year increase of 34.87%. It is expected to rise to 27.013 billion yuan with a growth rate of nearly 70.25% after 2023.
Compared with developed countries in Europe and the United States, the penetration rate of China’s health care products industry still has great room for improvement. In 2019, the penetration rate of Chinese health products in different age groups was between 10% – 30%, while the penetration rate of people aged 25 and over in developed countries such as the United States is currently between 50% – 75%.
Guolian Securities Co.Ltd(601456) said that the health products industry has dual attributes of food and medicine, and its scope is expanding towards both ends of “functional food” and “serious health products”. According to the prediction of China Business Industry Research Institute and Euromonitor, the scale of China’s functional food market will exceed 600 billion yuan in 2022. Therefore, from the perspective of broad health products, this is a trillion level super blue ocean.
Since the relevant production and business activities of NMN products were previously prohibited in the Chinese market, China’s NMN concept stocks are mainly engaged in the manufacturing of raw materials and production devices of NMN products. In addition, some concept stocks such as Xiamen Kingdomway Group Company(002626) and others are engaged in the production and sales of NMN products through overseas investment. The NMN market space is still very huge.
Citic Securities Company Limited(600030) said that as one of the ultimate human problems, prolonging life expectancy continued to increase the market attention and scale against the background of global economic growth and increasing population aging. In 2019, the global anti-aging market reached US $190 billion, an increase of 8.3% year-on-year. The health care products industry in China has developed rapidly in recent years, with a compound growth rate of 9.5% in the past 10 years. According to the calculation, the NMN market space corresponding to 1% of China’s health care product population is 30.4 billion yuan. With the continuous promotion of anti-aging products in the future, the long-term market of the industry is expected to reach 100 billion yuan.
